Default: The Lancet Neurology

ISSN: 1474-4422

Journal Home

Journal Guideline

The Lancet Neurology Q1 Unclaimed

Lancet Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Neurology is a journal indexed in SJR in Neurology (clinical) with an H index of 291. It has an SJR impact factor of 12,776 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 12,776.

The Lancet Neurology focuses its scope in these topics and keywords: disease, disorders, multiple, traumatic, diagnosis, cohort, cerebral, reality, sporadic, brain, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

The Lancet Neurology

12,776

SJR Impact factor

291

H Index

269

Total Docs (Last Year)

775

Total Docs (3 years)

5124

Total Refs

8742

Total Cites (3 years)

259

Citable Docs (3 years)

11,27

Cites/Doc (2 years)

19,05

Ref/Doc

Aims and Scope


disease, disorders, multiple, traumatic, diagnosis, cohort, cerebral, reality, sporadic, brain, patients, cns, flandersbelgian, decades, degenerationamyotrophic, devoted, clusterrandomised, clinical, classificationtime, als, alzheimers, babinski, balancing, belgian, benefits, breakthrough, caring, children, classification,



Best articles by citations

Neuromarketing: beyond branding

View more

Chris Polman: quietly making multiple sclerosis research tick

View more

Spinal-cord stimulation for reflex sympathetic dystrophy

View more

Stroke 1-2-0: a rapid response programme for stroke in China

View more

Molecular medicine for the brain: silencing of disease genes with RNA interference

View more

Patients have their say on research priorities

View more

Cytokines in sudden infant death syndrome

View more

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

View more

Acetylcholine and memory formation

View more

Fall-out from a possible transfusion-related transmission of vCJD

View more

Genetic testing and Huntington's disease: issues of employment

View more

Clazosentan for patients with subarachnoid haemorrhage: lessons learned

View more
SHOW MORE ARTICLES

Clazosentan for patients with subarachnoid haemorrhage: lessons learned -Authors' reply

View more

Cost-benefit analysis for epilepsy surgery

View more

Stroke in newborn infants

View more

Has the real potential of cloning technology been overlooked?

View more

AIDS and stroke risk

View more

Rat studies of Ritalin emphasise need for proper ADHD diagnosis

View more

New Indian centre to boost brain research and training

View more

Media Watch

View more

Media Watch

View more

Friedreich's ataxia: treatment within reach

View more

Yeast studies provide clues to neurodegeneration

View more

EU to crack down on inequality of MS treatment

View more

Comments

No comments ... Be the first to comment!

FAQS